Specifically, for the ICI-treated melanoma population, survival prospects consistently favored ROS1 mutation than its wild-type counterpart (HR 0.47, 95% CI 0.30–0.74; P = 0.009, Figure 2B). This evidence concerns the gene ROS1 and melanoma.